GlassScriptPhysician profile
Howard Menikoff
NPI 1720168529
$7,556.15
in general payments reported to CMS, 2019-2025
25 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,686 · 2020: $578 · 2021: $1,077 · 2022: $1,211 · 2023: $665 · 2024: $882 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,003.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,401.90 | 2019-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $1,153.77 | 2021-2025 | Orladeyo |
| Genzyme Corporation | $689.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $666.51 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $492.62 | 2019-2025 | Nucala, Trelegy Ellipta |
| Optinose US, INC. | $467.35 | 2019-2022 | |
| Csl Behring | $422.22 | 2019-2025 | Haegarda, Andembry |
| Pfizer INC. | $376.13 | 2019-2022 | |
| Alk-Abello, INC | $246.02 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $219.84 | 2019-2024 | Dupixent |
| Organon LLC | $191.25 | 2025 | Vtama |
| Dermavant Sciences, INC. | $187.17 | 2023-2024 | Vtama |
| Genentech USA, INC. | $169.42 | 2021-2025 | Xolair |
| Ionis Pharmaceuticals, INC. | $146.31 | 2025 | Dawnzera |
| Novartis Pharmaceuticals Corporation | $123.84 | 2019-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $94.54 | 2022-2024 | Actimmune |
| Grifols USA, LLC | $92.55 | 2023-2025 | Xembify |
| Merck Sharp & Dohme LLC | $89.67 | 2020-2023 | |
| Incyte Corporation | $88.45 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.99 | 2020-2023 | Takhzyro |
| Pharming Healthcare, INC. | $50.84 | 2020-2022 | |
| Shire North American Group INC | $46.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.26 | 2021 | |
| Leo Pharma INC. | $21.30 | 2024 | Adbry |
| Teva Pharmaceuticals USA, INC. | $16.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Menikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.